Barbara Büchel

Barbara Büchel

Auto-generated profile, based on publicly available information

Barbara Büchel

Institute of Clinical Chemistry, Inselspital, Bern University Hospital, and University of Bern, Bern, Switzerland

Research Focus & Metrics

Academic Career Length

25Years (2002-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
9 November 2012 in Cancer Chemotherapy and Pharmacology
Verified
Journal Article
Closed access
PDF file
FMF. Mueller
F. Mueller
BBB. Büchel
B. Büchel
DKD. Köberle
D. Köberle
SSS. Schürch
S. Schürch
BPB. Pfister
B. Pfister
Markus JoergerMarkus Joerger
Markus Joerger

27 March 2012 in Biomedical Chromatography
Verified
Journal Article
Closed access
PDF file
BBBarbara Büchel
Barbara Büchel
PRPeter Rhyn
Peter Rhyn
SSStefan Schürch
Stefan Schürch
CBClaudia Bühr
Claudia Bühr
UAUrsula Amstutz
Ursula Amstutz
Carlo LargiaderCarlo Largiader
Carlo Largiader

14 February 2013 in Clinical Chemistry and Laboratory Medicine (CCLM)
Verified
Journal Article
Closed access
BBBarbara Büchel
Barbara Büchel
JSJohanna Sistonen
Johanna Sistonen
Markus JoergerMarkus Joerger
Markus Joerger
YAYolanda Aebi
Yolanda Aebi
SSStefan Schürch
Stefan Schürch
Carlo LargiaderCarlo Largiader
Carlo Largiader
Background: Chemotherapies of solid tumors commonly include 5-fluorouracil (5-FU). With standard doses of 5-FU, substantial inter-patient variability has been observed in exposure levels and treatment response. Recently, improved outcomes in colorectal cancer patients due to pharmacokinetically guided 5-FU dosing were reported. We aimed at establishing a rapid and sensitive method for monitoring 5-FU plasma levels in cancer patients in our routine clinical practice. Methods: Performance of the Saladax My5-FU™ immunoassay was evaluated on the Roche Cobas® Integra 800 analyzer. Subsequently, 5-FU concentrations of 247 clinical plasma samples obtained with this assay were compared to the results obtained by liquid chromatography-tandem mass spectrometry (LC-MS/MS) and other commonly used clinical analyzers (Olympus AU400, Roche Cobas c6000, and Thermo Fisher CDx90). Results: The My-FU assay was successfully validated on the Cobas Integra 800 analyzer in terms of linearity, precision, accuracy, recovery, interference, sample carryover, and dilution integrity. Method comparison between the Cobas Integra 800 and LC-MS/MS revealed a proportional bias of 7% towards higher values measured with the My5-FU assay. However, when the Cobas Integra 800 was compared to three other clinical analyzers in addition to LC-MS/MS including 50 samples representing the typical clinical range of 5-FU plasma concentrations, only a small proportional bias (≤1.6%) and a constant bias below the limit of detection was observed. Conclusions: The My5-FU assay demonstrated robust and highly comparable performance on different analyzers. Therefore, the assay is suitable for monitoring 5-FU plasma levels in routine clinical practice and may contribute to improved efficacy and safety of commonly used 5-FU-based chemotherapies.

1 January 2002 in Die Innere Medizin
Verified
Journal Article
Open access
PDF file
SLS. Locher
S. Locher
BBB. Büchel
B. Büchel
HKHans-Peter Köhler
Hans-Peter Köhler
FNF. Nohl
F. Nohl
Die Leptospirose kommt in der Schweiz aufgrund der klimatischen Verhältnisse selten vor, trotzdem wird die Inzidenz dieser Krankheit unterschätzt. Das klinische Bild ist vielfältig. Die Differentialdiagnose reicht von einer grippeähnlichen Erkrankung bis hin zur akut verlaufenden Systemerkrankung. Diese Tatsache erfordert aufgrund der therapeutischen Konsequenz, die Durchführung einer intensiven und häufig auch invasiven Diagnostik, welche letztlich oft unergiebig bleibt. Neue und vor allem schnellere diagnostische Möglichkeiten mittels PCR aus Blut, Liquor und Urin werden diskutiert, sind aber noch nicht etabliert. Eine antibiotische Therapie wird je nach Verlaufsform kontrovers beurteilt.